Valuation dashboard for Bolt Biotherapeutics, Inc. (BOLT) with P/E N/A, P/B 0.49, EV/EBITDA -0.67 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Analysis Summary
Bolt Biotherapeutics, Inc. reported revenue of $7.7M in the most recent fiscal year, growing at a 5-year CAGR of 101.6%.
Trailing-twelve-month margins: gross margin 95.7%, operating margin -6.2%, net margin -6.1%.
At the current price of $3.63, BOLT has negative trailing earnings (P/E not meaningful) and an ROE of -125.92%. Market capitalisation stands at $7M.
Balance sheet quality for BOLT: current ratio of 3.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.49 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics, Inc. | $7M | 0.49 | -125.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.63 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -125.92% |
| Return on Invested Capital | -67.72% |
| Return on Assets | -58.81% |
| Gross Margin | 95.68% |
| Operating Margin | -623.04% |
| Net Margin | -611.47% |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks